Q: What is Opdivo used for?

Opdivo is used to treat the following conditions: melanoma non-small cell lung cancer renal cell carcinoma and others

Q: How does Opdivo work?

Immune Checkpoint Inhibition Opdivo is a monoclonal antibody that belongs to a class of drugs called PD-1 inhibitors. It works by targeting the programmed death receptor-1 (PD-1), a protein found on the surface of T-cells. T-cells are a type of white blood cell responsible for identifying and destroying abnormal cells, including cancer cells. Releasing the Brakes The immune system uses "checkpoints" to prevent it from attacking healthy cells. Cancer cells can sometimes use these checkpoints to hide from the immune system. They do this by binding to the PD-1 receptor on T-cells, which sends a signal to the T-cell to stop its attack. Opdivo works by: Binding to the PD-1 receptors on T-cells. Blocking cancer cells from connecting with these receptors. Preventing the cancer cells from sending a "stop" signal to the immune system. By blocking this interaction, Opdivo essentially releases the brakes on the immune system. This allows the T-cells to recognize the cancer cells as harmful and begin attacking them more effectively.

Q: What are the active ingredients in Opdivo?

The active ingredient in Opdivo is nivolumab .

Q: What are the side effects of Opdivo?

Common side effects of Opdivo may include: Fatigue Rash Pruritus and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Opdivo?

Opdivo belongs to the PD-1 inhibitor drug class.

Q: What is the dosage of Opdivo and how do I take it?

Administration Opdivo is administered by a healthcare professional in a medical setting, such as a hospital or infusion center. It is given in the following ways: Intravenous Infusion: The medication is infused into a vein over a period of 30 to 60 minutes. Subcutaneous Injection: Certain formulations may be administered as an injection under the skin. Dosing Schedule The treatment schedule varies depending on the condition being treated and whether the medication is used alone or in combination with other therapies. It is commonly administered once every 2, 3, 4, or 6 weeks. Your healthcare provider will determine the specific frequency and the total duration of your treatment based on your response to the medication. Missed Doses It is important to keep all scheduled appointments for your treatment. If you miss an appointment for a dose of Opdivo, call your healthcare provider immediately to reschedule your visit.

Q: Is Opdivo safe during pregnancy and breastfeeding?

Pregnancy Opdivo can cause harm to a fetus when administered to a pregnant person. Based on its mechanism of action and animal studies, the drug may interfere with the maintenance of pregnancy and increase the risk of immune-mediated disorders or fetal death. Before starting treatment, healthcare providers typically perform a pregnancy test for individuals who can become pregnant. It is important to use effective birth control ( contraception ) during treatment and for at least 5 months after the final dose of Opdivo. If you become pregnant or think you might be pregnant while receiving this medication, notify your healthcare provider immediately. Breastfeeding It is not known whether Opdivo passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least 5 months following the last dose. Patients should discuss the risks and benefits of breastfeeding with their healthcare team.

Q: What forms and strengths does Opdivo come in?

Opdivo is supplied in the following dosage forms: Intravenous Infusion: A liquid solution provided in single-dose vials. This form is diluted and administered into a vein by a healthcare provider. Subcutaneous Injection: A formulation containing nivolumab and hyaluronidase-nvhy, which is administered as an injection under the skin. The intravenous solution is typically a clear to opalescent, colorless to pale yellow liquid. Because these medications must be administered by a professional in a hospital or clinical setting, they are not available for self-administration at home.

Q: What is the FDA approval status of Opdivo?

FDA Approval History Opdivo received its initial FDA approval in December 2014 for the treatment of advanced melanoma. Since then, the FDA has expanded its approved uses to include a wide range of cancers, such as non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma. Approved Indications The FDA has granted approval for Opdivo to treat several specific conditions, often when the cancer is advanced or has returned after previous therapy. These include: Metastatic colorectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Hepatocellular carcinoma (liver cancer) in patients previously treated with sorafenib. Advanced or metastatic urothelial carcinoma (bladder cancer). Esophageal and gastric cancers. In many cases, Opdivo is approved for use as a single agent or in combination with other therapies, such as ipilimumab. Recent Regulatory Updates In February 2025, the FDA approved a subcutaneous version of the drug (nivolumab and hyaluronidase-nvhy). This formulation allows for a significantly shorter administration time compared to the traditional intravenous infusion. This approval covers all adult indications previously established for the intravenous form. Regulatory Classification Opdivo is a prescription-only medication. It is classified as a programmed death receptor-1 (PD-1) blocking antibody. While it is not subject to a Risk Evaluation and Mitigation Strategy (REMS) program, it is associated with severe immune-mediated adverse reactions that require close medical monitoring by healthcare providers.

Question 1

What is Opdivo?

Accepted Answer

Opdivo is a type of monoclonal antibody known as a programmed death receptor-1 (PD-1) blocking antibody. It functions as an immunotherapy by assisting the body's immune system in identifying and attacking cancer cells.

By targeting and blocking the PD-1 protein, the medication prevents certain cells from evading the immune response. This mechanism helps the immune system recognize and destroy these cells more effectively.

Question 2

What is Opdivo used for?

Accepted Answer

Opdivo is used to treat the following conditions:

melanoma
non-small cell lung cancer
renal cell carcinoma
and others

Question 3

How does Opdivo work?

Accepted Answer

Immune Checkpoint Inhibition

Opdivo is a monoclonal antibody that belongs to a class of drugs called PD-1 inhibitors. It works by targeting the programmed death receptor-1 (PD-1), a protein found on the surface of T-cells. T-cells are a type of white blood cell responsible for identifying and destroying abnormal cells, including cancer cells.

Releasing the Brakes

The immune system uses "checkpoints" to prevent it from attacking healthy cells. Cancer cells can sometimes use these checkpoints to hide from the immune system. They do this by binding to the PD-1 receptor on T-cells, which sends a signal to the T-cell to stop its attack.

Opdivo works by:

Binding to the PD-1 receptors on T-cells.
Blocking cancer cells from connecting with these receptors.
Preventing the cancer cells from sending a "stop" signal to the immune system.

By blocking this interaction, Opdivo essentially releases the brakes on the immune system. This allows the T-cells to recognize the cancer cells as harmful and begin attacking them more effectively.

Question 4

What are the active ingredients in Opdivo?

Accepted Answer

The active ingredient in Opdivo is nivolumab.

Question 5

What are the side effects of Opdivo?

Accepted Answer

Common side effects of Opdivo may include:

Fatigue
Rash
Pruritus
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Opdivo?

Accepted Answer

Opdivo belongs to the PD-1 inhibitor drug class.

Question 7

What is the dosage of Opdivo and how do I take it?

Accepted Answer

Administration

Opdivo is administered by a healthcare professional in a medical setting, such as a hospital or infusion center. It is given in the following ways:

Intravenous Infusion: The medication is infused into a vein over a period of 30 to 60 minutes.
Subcutaneous Injection: Certain formulations may be administered as an injection under the skin.

Dosing Schedule

The treatment schedule varies depending on the condition being treated and whether the medication is used alone or in combination with other therapies. It is commonly administered once every 2, 3, 4, or 6 weeks. Your healthcare provider will determine the specific frequency and the total duration of your treatment based on your response to the medication.

Missed Doses

It is important to keep all scheduled appointments for your treatment. If you miss an appointment for a dose of Opdivo, call your healthcare provider immediately to reschedule your visit.

Question 8

Is Opdivo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Opdivo can cause harm to a fetus when administered to a pregnant person. Based on its mechanism of action and animal studies, the drug may interfere with the maintenance of pregnancy and increase the risk of immune-mediated disorders or fetal death.

Before starting treatment, healthcare providers typically perform a pregnancy test for individuals who can become pregnant. It is important to use effective birth control (contraception) during treatment and for at least 5 months after the final dose of Opdivo. If you become pregnant or think you might be pregnant while receiving this medication, notify your healthcare provider immediately.

Breastfeeding

It is not known whether Opdivo passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least 5 months following the last dose. Patients should discuss the risks and benefits of breastfeeding with their healthcare team.

Question 9

What forms and strengths does Opdivo come in?

Accepted Answer

Opdivo is supplied in the following dosage forms:

Intravenous Infusion: A liquid solution provided in single-dose vials. This form is diluted and administered into a vein by a healthcare provider.
Subcutaneous Injection: A formulation containing nivolumab and hyaluronidase-nvhy, which is administered as an injection under the skin.

The intravenous solution is typically a clear to opalescent, colorless to pale yellow liquid. Because these medications must be administered by a professional in a hospital or clinical setting, they are not available for self-administration at home.

Question 10

What is the FDA approval status of Opdivo?

Accepted Answer

FDA Approval History

Opdivo received its initial FDA approval in December 2014 for the treatment of advanced melanoma. Since then, the FDA has expanded its approved uses to include a wide range of cancers, such as non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma.

Approved Indications

The FDA has granted approval for Opdivo to treat several specific conditions, often when the cancer is advanced or has returned after previous therapy. These include:

Metastatic colorectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Hepatocellular carcinoma (liver cancer) in patients previously treated with sorafenib.
Advanced or metastatic urothelial carcinoma (bladder cancer).
Esophageal and gastric cancers.

In many cases, Opdivo is approved for use as a single agent or in combination with other therapies, such as ipilimumab.

Recent Regulatory Updates

In February 2025, the FDA approved a subcutaneous version of the drug (nivolumab and hyaluronidase-nvhy). This formulation allows for a significantly shorter administration time compared to the traditional intravenous infusion. This approval covers all adult indications previously established for the intravenous form.

Regulatory Classification

Opdivo is a prescription-only medication. It is classified as a programmed death receptor-1 (PD-1) blocking antibody. While it is not subject to a Risk Evaluation and Mitigation Strategy (REMS) program, it is associated with severe immune-mediated adverse reactions that require close medical monitoring by healthcare providers.

Question 11

What should I know about Opdivo and cost?

Accepted Answer

Factors Affecting Cost

Several factors influence the total cost of treatment with Opdivo, including:

The specific condition being treated and the required dosage.
The frequency of infusions and the total duration of therapy.
Whether it is administered alone or in combination with other medications.
The type of health insurance coverage and out-of-pocket requirements like copays or deductibles.
The location of treatment, such as a hospital outpatient department or a private clinic.

Generic Availability

Opdivo is a brand-name biologic medication. There are currently no biosimilar or generic versions available, which generally contributes to its higher cost compared to older medications.

Financial Assistance

The manufacturer may offer support programs to help patients navigate insurance coverage or provide financial assistance to those who qualify. Patients are encouraged to speak with their healthcare provider or insurance company to understand the specific costs associated with their care.

Opdivo

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Opdivo

Hospitals.net Disclosure